Patents by Inventor Louise C. Showe

Louise C. Showe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250137066
    Abstract: Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of 7 or more selected genes, e.g., a gene expression profile, from the blood of the subject which is characteristic of disease. The gene expression profile includes 7 or more genes of Table I, Table II, Table III, Table IV or Table IX herein.
    Type: Application
    Filed: November 7, 2024
    Publication date: May 1, 2025
    Inventors: Michael Showe, Louise C. Showe, Andrew V. Kossenkov
  • Patent number: 12227808
    Abstract: Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of 7 or more selected genes, e.g., a gene expression profile, from the blood of the subject which is characteristic of disease. The gene expression profile includes 7 or more genes of Table I, Table II, Table III, Table IV or Table IX herein.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: February 18, 2025
    Inventors: Michael Showe, Louise C. Showe, Andrew V. Kossenkov
  • Publication number: 20230366034
    Abstract: Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of 10 or more selected genes, e.g., a gene expression profile, from the blood of the subject which is characteristic of disease. The gene expression profile includes 10 or more genes of Table I or Table II herein.
    Type: Application
    Filed: April 25, 2023
    Publication date: November 16, 2023
    Inventors: Michael Showe, Louise C. Showe, Andrei V. Kossenkov
  • Patent number: 11661632
    Abstract: Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of 10 or more selected genes, e.g., a gene expression profile, from the blood of the subject which is characteristic of disease. The gene expression profile includes 10 or more genes of Table I or Table II herein.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: May 30, 2023
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Michael Showe, Louise C. Showe, Andrei V. Kossenkov
  • Publication number: 20210079479
    Abstract: Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of 7 or more selected genes, e.g., a gene expression profile, from the blood of the subject which is characteristic of disease. The gene expression profile includes 7 or more genes of Table I, Table II, Table III, Table IV or Table IX herein.
    Type: Application
    Filed: December 19, 2018
    Publication date: March 18, 2021
    Inventors: Michael Showe, Louise C. Showe, Andrew V. Kossenkov
  • Patent number: 10745761
    Abstract: The present invention relates to methods and systems for high risk screening, diagnosis, prognosis, and surveillance of lung cancer. Accordingly, in one aspect, the invention provides a method for diagnosing or evaluating whether a subject has, or is at risk of having, lung cancer such as NSCLS. The method comprises obtaining a first expression level of the AKAP4 gene of a population of cells from the blood of a test subject; and comparing the first expression level with a first predetermined reference value. A difference between the first expression level and first predetermined reference value correlates with a diagnosis or evaluation of a lung cancer.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: August 18, 2020
    Assignees: Valley Health System, The Wistar Institute of Anatomy and Biology
    Inventors: Kiranmai Gumireddy, Qihong Huang, Louise C. Showe, Ganepola A Ganepola
  • Publication number: 20200131586
    Abstract: A multi-analyte composition for the diagnosis of lung cancer or lung disease comprises a ligand selected from a nucleic acid sequence, polynucleotide or oligonucleotide capable of specifically complexing with, hybridizing to, or identifying an mRNA gene transcript from a mammalian blood sample, and an additional ligand selected from a nucleic acid sequence, polynucleotide or oligonucleotide capable of specifically complexing with, hybridizing to, or identifying an miRNA of a gene from a mammalian blood sample. Each ligand and additional ligand binds to a different gene transcript or miRNA and the gene transcripts and miRNA identified form a characteristic profile of a stage of lung cancer or lung disease. Methods of using this composition for diagnosis and evaluation and methods for developing such compositions are described.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 30, 2020
    Inventors: Louise C. Showe, Michael K. Showe, Andrei V. Kossenkov
  • Publication number: 20190177799
    Abstract: The present invention relates to methods and systems for high risk screening, diagnosis, prognosis, and surveillance of lung cancer. Accordingly, in one aspect, the invention provides a method for diagnosing or evaluating whether a subject has, or is at risk of having, lung cancer such as NSCLS. The method comprises obtaining a first expression level of the AKAP4 gene of a population of cells from the blood of a test subject; and comparing the first expression level with a first predetermined reference value. A difference between the first expression level and first predetermined reference value correlates with a diagnosis or evaluation of a lung cancer.
    Type: Application
    Filed: June 2, 2015
    Publication date: June 13, 2019
    Applicants: Valley Health System, The Wistar Institute
    Inventors: Kiranmai Gumireddy, Qihong Huang, Louise C. Showe, Ganepola A. Ganepola
  • Patent number: 10238755
    Abstract: Compositions and methods described herein include somatic cells that are competent for reprogramming and malignant transformation and are characterized by a reduction of the levels of Sp100 in the cells, cells having markers of pluripotent stem cells, and methods for preparing same. Methods for reversably regulating aging or reprogramming to pluripotency in a somatic cell involve modulating the expression of Sp100 therein. Methods and compositions for retarding the growth of or suppressing unwanted cell proliferation involve expressing, inducing expression of, or upregulating, Sp100 in a targeted cell that is undergoing unrestricted proliferation or replication or increasing exposure to Sp100 in the environment or microenvironment of the targeted cell. Also disclosed are methods for treating a proliferative disease or condition by increasing expression or levels of Sp100 in the targeted cell or its environment.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: March 26, 2019
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Gerd G. Maul, Dmitri G. Negorev, Louise C. Showe, Olga V. Vladimirova
  • Publication number: 20190085407
    Abstract: An isoform-level gene panel is disclosed that can accurately classify a glioblastoma subtype from a tumor sample. Such an isoform level gene panel comprises the 121 to 214 target isoforms identified in Table 1. Also disclosed are reagents for quantitively detecting the expression or activity of the target isoforms of Table 1 in a patient sample. For example, such ligands can be PCR primer and probes sets. This isoform-level gene panel and reagents for detection of the isoforms are useful in an isoform-level assay for diagnosis of the molecular subtype of a glioblastoma in a patient. The assay employs algorithms and a novel computer program that performs the functions of FIG. 8. In one aspect, the assay is a high-throughput format.
    Type: Application
    Filed: October 17, 2018
    Publication date: March 21, 2019
    Inventors: Ramana V. Davuluri, Sharmistha Pal, Yingtao Bi, Louise C. Showe, Donald M. O'Rourke, Luke Macyszyn
  • Patent number: 10113201
    Abstract: An isoform-level gene panel is disclosed that can accurately classify a glioblastoma subtype from a tumor sample. Such an isoform level gene panel comprises the 121 to 214 target isoforms identified in Table 1. Also disclosed are reagents for quantitatively detecting the expression or activity of the target isoforms of Table 1 in a patient sample. For example, such ligands can be PCR primer and probes sets. This isoform-level gene panel and reagents for detection of the isoforms are useful in an isoform-level assay for diagnosis of the molecular subtype of a glioblastoma in a patient. The assay employs algorithms and a novel computer program that performs the functions of FIG. 8. In one aspect, the assay is a high-throughput format.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: October 30, 2018
    Assignees: The Wistar Institute of Anatomy and Biology, The Trustees of the University of Pennsylvania
    Inventors: Ramana V. Davuluri, Sharmistha Pal, Yingtao Bi, Louise C. Showe, Donald M. O'Rourke, Luke Macyszyn
  • Publication number: 20180142303
    Abstract: A multi-analyte composition for the diagnosis of lung cancer or lung disease comprises a ligand selected from a nucleic acid sequence, polynucleotide or oligonucleotide capable of specifically complexing with, hybridizing to, or identifying an mRNA gene transcript from a mammalian blood sample, and an additional ligand selected from a nucleic acid sequence, polynucleotide or oligonucleotide capable of specifically complexing with, hybridizing to, or identifying an miRNA of a gene from a mammalian blood sample. Each ligand and additional ligand binds to a different gene transcript or miRNA and the gene transcripts and miRNA identified form a characteristic profile of a stage of lung cancer or lung disease. Methods of using this composition for diagnosis and evaluation and methods for developing such compositions are described.
    Type: Application
    Filed: May 19, 2016
    Publication date: May 24, 2018
    Inventors: Louise C. Showe, Michael K. Showe, Andrei V. Kossenkov
  • Patent number: 9920375
    Abstract: Methods and compositions are provided for diagnosing or detecting a condition, e.g., lung disease in a mammalian subject by use of a micro-RNA expression level or an expression level profile of multiple miRNA in the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of COPD or NSCLC. Detection of changes in expression in specific miRNA biomarkers from that of a reference sample or miRNA expression profile are correlated with non-small cell lung cancer (NSCLC) and/or COPD and permit differentiation among healthy subjects, subjects with COPD and subjects with adenocarcinoma or squamous cell carcinoma.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: March 20, 2018
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Louise C. Showe, Michael Showe, Andrew V. Kossenkov, Elena Nikonova
  • Publication number: 20160060704
    Abstract: An isoform-level gene panel is disclosed that can accurately classify a glioblastoma subtype from a tumor sample. Such an isoform level gene panel comprises the 121 to 214 target isoforms identified in Table 1. Also disclosed are reagents for quantitatively detecting the expression or activity of the target isoforms of Table 1 in a patient sample. For example, such ligands can be PCR primer and probes sets. This isoform-level gene panel and reagents for detection of the isoforms are useful in an isoform-level assay for diagnosis of the molecular subtype of a glioblastoma in a patient. The assay employs algorithms and a novel computer program that performs the functions of FIG. 8. In one aspect, the assay is a high-throughput format.
    Type: Application
    Filed: April 4, 2014
    Publication date: March 3, 2016
    Inventors: Ramana V. Davuluri, Sharmistha Pal, Yingtao Bi, Louise C. Showe, Donald M. O'Rourke, Luke Macyszyn
  • Patent number: 9068974
    Abstract: Methods and compositions are provided for diagnosing or detecting a condition, e.g., lung disease in a mammalian subject by use of a micro-RNA expression level or an expression level profile of multiple miRNA in the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of COPD or NSCLC. Detection of changes in expression in specific miRNA biomarkers from that of a reference sample or miRNA expression profile are correlated with non-small cell lung cancer (NSCLC) and/or COPD and permit differentiation among healthy subjects, subjects with COPD and subjects with adenocarcinoma or squamous cell carcinoma.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: June 30, 2015
    Assignee: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
    Inventors: Louise C. Showe, Michael Showe, Andrew V. Kossenkov, Elena Nikonova
  • Publication number: 20140308255
    Abstract: Compositions and methods described herein include somatic cells that are competent for reprogramming and malignant transformation and are characterized by a reduction of the levels of Sp100 in the cells, cells having markers of pluripotent stem cells, and methods for preparing same. Methods for reversably regulating aging or reprogramming to pluripotency in a somatic cell involve modulating the expression of Sp100 therein. Methods and compositions for retarding the growth of or suppressing unwanted cell proliferation involve expressing, inducing expression of, or upregulating, Sp100 in a targeted cell that is undergoing unrestricted proliferation or replication or increasing exposure to Sp100 in the environment or microenvironment of the targeted cell. Also disclosed are methods for treating a proliferative disease or condition by increasing expression or levels of Sp100 in the targeted cell or its environment.
    Type: Application
    Filed: November 29, 2012
    Publication date: October 16, 2014
    Inventors: Gerd G. Maul, Dmitri G. Negorev, Louise C. Showe, Olga V. Vladimirova
  • Publication number: 20110251098
    Abstract: Methods and compositions are provided for diagnosing or detecting a condition, e.g., lung disease in a mammalian subject by use of a micro-RNA expression level or an expression level profile of multiple miRNA in the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of COPD or NSCLC. Detection of changes in expression in specific miRNA biomarkers from that of a reference sample or miRNA expression profile are correlated with non-small cell lung cancer (NSCLC) and/or COPD and permit differentiation among healthy subjects, subjects with COPD and subjects with adenocarcinoma or squamous cell carcinoma.
    Type: Application
    Filed: November 6, 2009
    Publication date: October 13, 2011
    Inventors: Louise C. Showe, Michael Showe, Andrew V. Kossenkov, Elena Nikonova
  • Patent number: 7640114
    Abstract: A method of developing a gene expression profile indicative of the presence or stage of a selected a disease, disorder or genetic pathology in a mammalian subject employs penalized discriminant analysis with recursive feature elimination. A method of diagnosing a cancer in a mammalian subject includes the steps of examining a sample containing the subject's immune cells and detecting a variance in the expression of a statistically significant number of genes, e.g., at least 10 non-tumor genes from those same genes in a characteristic disease or healthy gene expression profile. A significant variance in expression of these genes when compared to a gene expression profile, preferably an average gene expression profile of a normal control, or significant similarities to an average gene profile of subjects with cancer, correlates with a specific type of cancer and/or location of tumor.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: December 29, 2009
    Assignee: The Wistar Institute of Anatomy & Biology
    Inventors: Louise C. Showe, Michael K. Showe, Laszlo Kari, Michael Nebozhyn, Andrey Loboda
  • Patent number: 7514219
    Abstract: The present invention is a method distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma. In particular, a 10-gene classifier has been identified which can be used to distinguish between primary squamous cell carcinoma of the lung and metastatic head and neck squamous cell carcinoma. These genes include CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2. A panel of one or more of these genes, or proteins encoded thereby, can be used for early diagnosis and selection of an appropriate therapeutic treatment.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: April 7, 2009
    Assignees: The Wistar Institute, Trustees of the University of Pennsylvania
    Inventors: Louise C. Showe, Michael Nebozhyn, Anil Vachani, Steven M. Albelda
  • Patent number: 5079147
    Abstract: Novel DNA sequences located 5' to the chromosome 11p13 breakpoint are employed as diagnostic probes for breast cancers, T cell leukemias and WAGR associated with chromosome 11 abnormalities. Probe compositions and methods for diganostic assays are provided.
    Type: Grant
    Filed: March 13, 1989
    Date of Patent: January 7, 1992
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Louise C. Showe, Richard C. Harvey